The EIF4A3/circFADS1/GSK3β/β‐catenin axis is discovered to hold promise as a novel therapeutic target for hepatocellular carcinoma, while circFADS1 is also a significant factor in lenvatinib resistance. Here, EIF4A3 is linked to hepatocellular carcinoma.